Tenax Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 83   

Articles published

TENX 3.80 +0.02 (0.53%)
price chart
UPDATE: MLV Initiates Coverage On Tenax Therapeutics
The United States Food and Drug Administration recently granted Fast Track status for levosimendan, and Tenax enrolled their first patient in the Phase III study in September.
Tenax Therapeutics Announces Second Quarter Fiscal Year 2015 Financial ...
MORRISVILLE, N.C., Dec 17, 2014 (BUSINESS WIRE) -- Tenax Therapeutics, Inc. TENX, +0.53% a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced financial ...
Tenax Therapeutics' (TENX) CEO John Kelley on Q2 2015 Results - Earnings ...  Seeking Alpha
Related articles »  
Oxygen Biotherapeutics Announces Name Change to Tenax Therapeutics
MORRISVILLE, N.C., Sep 16, 2014 (BUSINESS WIRE) -- Oxygen Biotherapeutics, Inc. OXBT a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the ...
Beleagured Morrisville drug developer changes name, sharpens focus  Triangle Business Journal
Related articles »  
Tenax Therapeutics Inc.: Tenax Therapeutics to Provide Corporate Update and ...
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the Company will ...
Related articles »  
Tenax Therapeutics Announces First Patients Enrolled in Phase 3 LEVO-CTS ...
MORRISVILLE, N.C., Sep 22, 2014 (BUSINESS WIRE) -- Tenax Therapeutics, Inc. TENX, -1.30% formerly Oxygen Biotherapeutics, Inc., a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical ...
Morrisville's Tenax studies experimental drug in cardiac surgery patients  Triangle Business Journal
Related articles »  
Tenax Therapeutics Announces First Quarter Fiscal Year 2015 Financial Results
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX), formerly Oxygen Biotherapeutics, Inc., a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, ...
Tenax Therapeutics' (TENX) CEO John Kelley on Q1 2015 Results - Earnings ...  Seeking Alpha (registration)
Related articles »  
Tenax Therapeutics to Provide Corporate Update and Discuss First Quarter ...
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX), formerly Oxygen Biotherapeutics, Inc., today announced that the Company will host a conference call and live audio webcast on Wednesday, September 24, 2014, at 8:30 ...
Related articles »  
Achillion Pharmaceuticals Inc (ACHN), Tenax Therapeutics Inc (TENX): Peter ...
As a result, RA Capital Management is left holding 8.03 million shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). In another move, the fund's manager, Peter Kolchinsky, has initiated a position in Tenax Therapeutics Inc (NASDAQ:TENX). According ...
Related articles »  
Tenax Therapeutics Q2 Loss Narrows - Quick Facts
(RTTNews.com) - Tenax Therapeutics Inc. ( TENX ), formerly Oxygen Biotherapeutics Inc., a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, reported that its net loss ...
Oxygen Biotherapeutics Now Covered by Analysts at MLV & Co (TENX)  Intercooler
Related articles »  
Oxygen Biotherapeutics, Inc. (OXBT) news: Oxygen Biotherapeutics surges after ...
Oxygen Biotherapeutics' (OXBT) shares soar 30% after the FDA verbally lifts a hold on clinical trials of the company's Oxycyte treatment for traumatic brain injury (TBI). The FDA's decision comes after Oxygen submitted animal study data in September ...
Related articles »